Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
TransDigm Group Incorporated ( TDG - Analyst Report ) reported second-quarter fiscal 2012 earnings per share from continuing operations of $1.51, outpacing the Zacks Consensus Estimate of $1.30 and prior-year earnings per share of 69 cents.
Revenue
Net sales were $423.5 million, up 39.2% year over year. Organically, sales during the quarter surged approximately 14.9%, driven by increased sales in commercial OEM markets and aided by acquisitions of Schneller, Harco and Amsafe.
Income & Expenses
Income from operations for the quarter was $177.2 million compared with $113.2 million in the prior-year period. Selling and administrative expenses were $49.5 million compared with $33.2 million in the comparable quarter last year. EBITDA for the quarter jumped $192.5 million from $128.3 million.
Balance Sheet & Cash Flow
Cash and cash equivalents were $201.5 million at the end of the quarter compared with $376.2 million at the end of fiscal 2011. Long-term debt was $3.6 billion while shareholders equity was $994.9 million at the end of the quarter.
Net cash from operating activities was $164.8 million in the quarter compared with $129.2 million in the prior-year period.
Outlook
Driven by the robust performance in the second quarter, the company raised its full year 2012 guidance. TransDigm expects its total revenue for fiscal 2012 to be in the range of $1,670 million to $1,698 million, up from its prior guidance range of $1,470 million to $1,510 million. Further, earnings per share are expected to be in the range of $5.47 to $5.82, up from its prior guidance of $5.15 to $5.49. Adjusted earnings per share are expected to be in the range of $6.23 to $6.57, up from its prior guidance range of $5.66 to $6.00.
The company revised its guidance to account for the recent acquisition of AmSafe and good performance in the first half of the year. However, uncertain aerospace market and worldwide economic environment remain a matter of concern.
Based in Cleveland, Ohio, TransDigmGroup Inc.designs, produces, and supplies engineered aircraft components for use on commercial and military aircraft. The company operates principally in the US. Major competitors of the company are Goodrich Corp. ( ) , Honeywell International Inc. ( HON - Analyst Report ) and United Technologies Corp. ( UTX - Analyst Report ) .
We continue to maintain an Outperform rating on TranDigm for the long term. The company has a Zacks #1 Rank (Strong-Buy recommendation) over the next one-to-three months.
Read the full reports :
Analyst Report on HON
Analyst Report on UTX
Analyst Report on TDG